Chemocentryx, Inc.

Jeffrey Mcmahon

Rajinder Paul Singh

Penglie Zhang

Manmohan Reddy Leleti

Sreenivas Punna

Venkat Reddy Mali

Ju Yang

Viengkham Malathong

Hiroko Tanaka

Darren J McMurtrie

Antoni Krasinski

Dean R Dragoli

Jaroslaw Kalisiak

Junfa Fan

Xi Chen

Chao Yu

James J Campbell

Howard S Roth

Karen Ebsworth

Hiroko Tankaka

The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula:

Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2

Growing community of inventors

San Francisco, CA, United States of America

Jeffrey Mcmahon